Výsledky vyhledávání - David Shamblaw
- Zobrazuji výsledky 1 - 5 z 5
-
1
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate Autor Gregory Huhn, David Shamblaw, Jean‐Guy Baril, Priscilla Y. Hsue, Brittany L Mills, Thai Nguyen-Cleary, Scott McCallister, Moupali Das
Vydáno 2019Artigo -
2
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil... Autor Calvin Cohen, Richard Elion, Peter Ruane, David Shamblaw, Edwin DeJesus, Bruce Rashbaum, Steven L. Chuck, Kitty Yale, Hui C. Liu, David R. Warren, S. Ramanathan, Brian P. Kearney
Vydáno 2011Artigo -
3
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppre... Autor Frank J. Palella, Martin Fisher, Pablo Tebas, Brian Gazzard, Peter Ruane, Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Danielle Porter, Kirsten L. White, Jason Hindman, Elizabeth Elbert, Shampa De-Oertel, Todd Fralich
Vydáno 2013Artigo -
4
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy Autor Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister
Vydáno 2015Artigo -
5
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-cont... Autor Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva, Giovanni DiPerri, Jan van Lunzen, Ellen Koenig, Richard Elion, Matthias Cavassini, Jose Valdez Madruga, Jason Brunetta, David Shamblaw, Edwin DeJesus, Chloe Orkin, David A. Wohl, Indira Brar, Jeffrey L. Stephens, Pierre-Marie Girard, Gregory Huhn, Andrew Plummer, Ya-Pei Liu, Andrew Cheng, Scott McCallister
Vydáno 2015Artigo
Vyhledávací nástroje:
Související témata
Antiretroviral therapy
Human immunodeficiency virus (HIV)
Medicine
Viral load
Virology
Internal medicine
Cobicistat
Emtricitabine
Pharmacology
Regimen
Tenofovir
Tenofovir alafenamide
Clinical endpoint
Elvitegravir
Oncology
Protease inhibitor (pharmacology)
Reverse-transcriptase inhibitor
Rilpivirine
Adverse effect
Clinical trial
Confidence interval
Disease
Efavirenz
Gastroenterology
Randomized controlled trial
Ritonavir
Tolerability